Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

597
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
597
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

718
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
718
Glaucoma: Overview01:25

Glaucoma: Overview

792
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
792

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Use of Generative Artificial Intelligence in Systematic Literature Reviews: A Rapid Review of the Literature.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Harms Reporting Was Frequently Incomplete or Discordant in Biomedical Randomized Trials Published in 2023: A Meta-epidemiological Study.

Journal of clinical epidemiology·2026
Same author

Masquerading disease of macular telangiectasia type 2 - MacTel Project Report No 11.

Ophthalmology. Retina·2026
Same author

Evaluating the accuracy and speed of eight deduplication tools: A comparative study.

Research synthesis methods·2026
Same author

Influence of Social and Demographic Factors on Retinoblastoma Outcomes in the United States: A Systematic Review.

Cochrane evidence synthesis and methods·2026
Same author

Choroidal vascularity across aging and the spectrum of age-related macular degeneration: an AI-based OCT study.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026

Related Experiment Video

Updated: Sep 19, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.3K

Interventions for central serous chorioretinopathy: a network meta-analysis.

Clemens Ak Lange1,2, Riaz Qureshi3,4, Laurenz Pauleikhoff2,5

  • 1Department of Ophthalmology, St Franziskus Hospital, Münster, Germany.

The Cochrane Database of Systematic Reviews
|June 16, 2025
PubMed
Summary

This review found no significant differences in effectiveness among various treatments for central serous chorioretinopathy (CSC). Low-dose photodynamic therapy (PDT), supplements, and eplerenone showed potential but with low-certainty evidence, warranting further research.

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

6.8K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.2K

Related Experiment Videos

Last Updated: Sep 19, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.3K
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

6.8K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.2K

Area of Science:

  • Ophthalmology
  • Retinal Diseases
  • Choroidal Disorders

Background:

  • Central serous chorioretinopathy (CSC) involves choroidal thickening and retinal detachment, potentially causing irreversible vision loss.
  • Current interventions for CSC include laser treatment, photodynamic therapy (PDT), and various drug therapies, but evidence for their long-term efficacy is lacking.
  • There is no established evidence-based consensus for managing CSC.

Purpose of the Study:

  • To assess the comparative effectiveness of multiple interventions for CSC.
  • To provide a relative ranking of CSC interventions using network meta-analysis (NMA).
  • To update a previous Cochrane review on CSC interventions.

Main Methods:

  • Conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing CSC interventions.
  • Searched multiple databases (CENTRAL, MEDLINE, Embase) and trial registries up to March 2024.
  • Extracted data on visual acuity, recurrence, persistence, contrast sensitivity, retinal thickness, quality of life, and adverse events; assessed risk of bias using CINeMA.

Main Results:

  • Included 67 RCTs with 4015 participants; most trials were small, poorly reported, and at moderate risk of bias.
  • Pairwise meta-analyses generally found no significant differences between treatments.
  • NMA for best corrected visual acuity (BCVA) did not show superiority of any treatment; low-dose PDT, supplements, and eplerenone ranked highest but with very low to moderate certainty of evidence.

Conclusions:

  • No single treatment for CSC demonstrated superiority over others based on current evidence.
  • Low-dose PDT, supplements, and eplerenone may offer potential benefits for visual acuity, but evidence is limited and requires further high-quality RCTs.
  • Larger, high-quality RCTs are needed to establish evidence-based management guidelines for CSC.